BONESUPPORT HOLDING AB (publ) – publishes Q2 2024 Interim report

Published: 2024-07-11

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2024.

55% SALES GROWTH IN THE FIRST SIX MONTHS

APRIL - JUNE 2024

  • Net sales increased by 57 percent (55 percent at constant exchange rates) and amounted to SEK 219.8 million (140.4).
  • The North America (NA) segment reported a sales growth of 67 percent (66 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (26 percent at constant exchange rates).
  • The gross margin amounted to 92.3 percent (91.3).
  • The operating result before effects from the Group’s incentive programs amounted to SEK 36.0 million (13.6). Reported operating result amounted to SEK 28.7 million (6.0).
  • Earnings per share before dilution were SEK 0.42 (0.08).
  • Earnings per share after dilution were SEK 0.41 (0.08).

JANUARY - JUNE 2024

  • Net sales increased by 55 percent (54 percent at constant exchange rates) and amounted to SEK 404.2 million (260.1).
  • The North America (NA) segment reported a sales growth of 66 percent (65 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 28 percent (26 percent at constant exchange rates).
  • The gross margin amounted to 92.4 percent (90.9)
  • Operating result before effects from the Group’s incentive programs amounted to SEK 77.6 million (18.2). Reported operating result amounted to SEK 61.0 million (6.7).
  • Earnings per share before dilution were SEK 0.75 (0.09).
  • Earnings per share after dilution were SEK 0.74 (0.08).

"Strong sales – raised guidance for 2024." Emil Billbäck, CEO


EVENTS DURING THE PERIOD

  • In June, the results of an Australian study in the treatment of bone infection resulting from diabetes-related foot ulcers were presented. The results of the study show that the use of CERAMENT G or CERAMENT V not only significantly reduces the risk of amputation and surgical procedures, but also promotes effective healing and shorter hospital stays compared to the control group.
  • CMS announced proposal to extend NTAP for CERAMENT G in the US until September 2025. Final decision expected in August 2024.

EVENTS AFTER THE PERIOD

  • The FDA announced that CERAMENT V must follow the regulatory 510(k) process for applying for market authorization.
  • Anna Stegmark is hired as Executive Vice President Quality and Regulatory Affairs.
  • Increase in forecast for 2024 sales growth to over 50 percent (previous forecast was over 40 percent).

For more information contact:

BONESUPPORT AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-11 08:00 CEST.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

Bonesupport Q2 2024 EN